Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)

by NASDAQ Market News August 5, 2019

NASDAQ Market News
Click here to email author

Influenza Diagnostic Tests Market to hit $1.5 billion by 2025: Global Market Insights, Inc.

Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer

Ads